#moderna-stock-performance

#moderna-stock-performance

President Trump posted on social media that Iran's new regime president has asked the U.S. for a ceasefire, with Trump signaling he'd consider it once the Strait of Hormuz is open and clear.

mRNA vaccines have demonstrated their ability to prevent approximately eight million COVID infections within the first six months of their rollout, showcasing their effectiveness in combating the pandemic.

Anthropic has purchased the stealth biotech AI startup Coefficient Bio in a $400 million stock deal, confirming its commitment to advancing healthcare and life sciences.

Incyte tops this list due to its rare combination of commercial scale, cash generation, and pipeline depth. The company posted FY2025 revenue of $5.14 billion, up 21.2% YoY, anchored by Jakafi generating $828.2 million in Q4 2025 alone (+7% YoY) and Opzelura delivering $207.3 million (+28% YoY). With $3.58 billion in cash and 14 pivotal clinical trials underway, Incyte offers an acquirer immediate revenue, margin expansion potential, and a deep oncology pipeline spanning KRASG12D, CDK2 inhibition, and mutCALR.

Today represents the first real acknowledgement that team and those scientists have gotten that their technology was instrumental in Covid-19 vaccines, or at least the Moderna vaccine as we're announcing today with this settlement. This settlement validates the scientific contributions made by the researchers at Arbutus and Genevant in developing the lipid nanoparticle delivery system.

Oppenheimer frames Ocugen as an emerging gene therapy leader in blinding ocular disorders, with the investment thesis centered squarely on the company's lead asset, OCU400. The firm views a potential 2027 approval as a near-term entry point into what it describes as a 'sizable and poorly-met rare disease market opportunity.' The core appeal is OCU400's gene-agnostic mechanism: unlike the only existing approved retinitis pigmentosa therapy, Luxturna, which targets just one of 100+ RP-associated genes, OCU400 is designed to address the broad RP patient population with a single one-time injection.

Bernstein's analysis suggests that the recent selloff creates an attractive entry point for investors, emphasizing that TurboQuant should have 'zero impact' on hard disk drive demand and 'negligible impact' on NAND demand.

Zacks Investment Research assigned Micron its top Rank #1 (Strong Buy) rating this morning, citing the company's "significant role in the AI boom" and noting that Micron's 2026 HBM capacity is already sold out, driven by demand from AI chip partners including NVIDIA, Advanced Micro Devices, and Intel.

Guggenheim analyst Seamus Fernandez raised his firm's price target on AstraZeneca to 16,500 GBp from 16,000 GBp, maintaining a Buy rating after updating the firm's model ahead of Q1 earnings.

While the move came as a surprise to the high-profile vaccine maker, it is just the latest hostility toward vaccines-and mRNA vaccines in particular-from an agency overseen by the fervent anti-vaccine activist Robert F. Kennedy Jr. In his first year in office, Kennedy has already dramatically slashed childhood vaccine recommendations and canceled $500 million in research funding for mRNA vaccines against potential pandemic threats.

The news is the latest sign of the FDA's heightened scrutiny of vaccines under Health Secretary Robert F. Kennedy Jr., particularly those using mRNA technology, which he has criticized before and after becoming the nation's top health official. Moderna received what's called a "refusal-to-file" letter from the FDA that objected to how it conducted a 40,000-person clinical trial comparing its new vaccine to one of the standard flu shots used today.

Strong digital advertising growth hasn't been enough to keep social media stocks afloat, with fears about AI disruption and broader economic issues gripping Wall Street.

As for side effects, the companies reported that little had changed from previous analyses; adverse events were similar between the two groups. The top side effects linked to the vaccine were fatigue, injection site pain, and chills. The results "highlight the potential of a prolonged benefit" of the vaccine combined with Keytruda in patients with high-risk melanoma," Kyle Holen, a senior vice president at Moderna, said. They also "illustrate mRNA's potential in cancer care," he said, noting that the company has eight more Phase 2 and Phase 3 trials going for mRNA vaccines against a variety of other cancers, including lung, bladder, and kidney cancers.